Tag archives: LYTAC

BOC Sciences Demonstrates Comprehensive Strength with LYTAC Technology

New York, United States—June 29, 2022—BOC Sciences, a leading CRO in the pharmaceutical industry, demonstrates its comprehensive strength through innovative lysosome-targeting chimera (LYTAC) degradation technology solutions developed within the field of targeted protein degradation.


LYTAC is a new technology that can degrade extracellular proteins and membrane-related proteins through the endosomal/lysosomal pathway. The ...

Continue reading